Market Overview
Global Peptide Therapeutics Market size accrued earnings worth approximately USD 45.67 billion in 2023 and is predicted to gain revenue of about USD 74.76 billion by 2032, is set to record a CAGR of nearly 5.63% over the period from 2024 to 2032.
Incorporation in pipeline studies of these new peptides coupled with the surge of malignancy and metabolic disorders like osteoporosis, obesity, and diabetes is seen boosting peptide therapeutics use in future. Increasing Paediatric cases and large number of population cases in deprived countries demand need for affordable and safe medicine.
Rise in the prevalence of multiple cancers and an increase in the need for appropriate treatment options will surge the market growth. For example, as per International Agency for Research on Cancer, over 20.7 million new cancer cases are estimated for 2023. Peptide therapeutic development can treat cancer at an early stage, and this treatment could enhance disease management and decrease mortality. Market growth in the forecast period is likely to be driven by rising demand for effective and fast-acting medicines. World Cancer Report 2020 attributes 10 million deaths of this year to cancer, with one in six deaths being due to cancer. Cancer-related deaths are one-third because of smoking, high body mass index, alcohol abuse, obesity, and high cholesterol.
During the forecast period, it is anticipated that the market would grow lucratively due to CAGR, mainly due to companies working on new drug development. Companies are focused on doing a great amount of research and development for new treatment development concerning targeted diseases in order to raise market shares. Peptide therapeutic R&D focus on metabolic disorders and then on oncology, and after that on infectious diseases. In the area of peptide therapeutics, there is an observed shift towards increasing stringent regulations related to efficacy, safety, and quality requirements for approval. FDA and EMA are proactively reviewing new guidelines to further standardize and make the process easier for approval in peptide therapeutics.
However, the limited capacity of solid-phase reactors hampers purification and the maintenance of a sizeable quantity of long peptides to be chemical-functionalized and swell resins. Increasing modifications and unnatural amino acid addition make synthesis much more complicated. The length, 3D conformations, and the variety of modified amino acid residues in some of these developed peptides are causing complications in separating and purifying them.
Market Drivers
Rising Prevalence of Chronic Diseases
The most major driving force responsible for the increment in demand related to peptide-based drugs includes an increase in incidences of various cancers, diabetes and obesity, heart diseases, as well as infectious diseases. Due to their high degree of specificity and potency along with a far more favourable safety profile than compared to traditional small molecules, peptides represent an essential tool in modern drug discovery today. Recent aspects of peptide-based therapies in oncology include targeted drug delivery and immune system modulation. For example, GLP-1 receptor agonists peptides can enhance diabetic and obesity statuses by regulating insulin homeostasis and body weight. Cardiovascular disease treatments through peptide-based medications also influence the regulation of blood pressure as well as cholesterol metabolism. With continuously increasing importance of infectious diseases, research in the field of peptide-based antimicrobials and vaccines has accelerated. Chronic diseases have taken the centre stage as a result of both aging populations and lifestyles, and the development of peptide therapeutics has captured the spotlight in the pharmaceutical market as the most promising alternative treatment. Research, development, and growth in the market are accelerating as a result.
Market Opportunities
Technological Advancements in Drug Delivery
Advances in peptide drug delivery, including long-acting injectables, oral peptides, and nanoparticle-based systems, significantly increase market potential. For chronic diseases such as diabetes and cancer, long-acting injectables have improved compliance by making dosing less frequent for patients, thereby facilitating more convenient treatments for chronic conditions. Oral peptides, which have previously been difficult because of hydrolytic degradation in the gastrointestinal tract, are now gaining feasibility through improvements in formulation that improve stability and absorption. Besides the availability of peptide therapeutics only by injections, this innovation actually enables wider penetration and application in various routes. Further, the nanoparticle-based delivery systems enable targeted and controlled release of drugs, thus enhancing bioavailability and minimizing side effects. Such improved half-lives increase dosing regimens and overall patient outcomes in the treatment of disease conditions. Because of pharmaceutical companies investing more in new delivery technologies, the market for peptide therapeutics is growing based on an insatiable demand for the treatment of most medical conditions using better, convenient, and friendlier treatment approaches.
Market Restraining Factors
Short Half-life and Stability Issues
Many peptides are rapidly degraded by enzymes and are quickly metabolized out of the bloodstream. This would necessitate dosing at short intervals to achieve optimal therapeutic effects. This might be inconvenient to the patient, especially when the disease is chronic such as diabetes, cancer, and cardiovascular diseases. Frequent injections can become painful for the patient and lead to poor patient compliance to a treatment regime. This may generally affect health outcomes. To address this, several strategies of modifying peptides, encapsulating them into nanoparticles, and creating long-acting formulations are in development to increase half-life and stability. Pegylation-attach polyethylene glycol chains-and lipidation-make modifications to peptides with lipid molecules-to slow down the degradation process and circulate in the body for a longer period. Moreover, injectables with sustained release and implantable delivery systems are under development to decrease the dosing frequency. It is important that the short half-life issue be overcome for peptide-based therapeutics to become widely used and improve patient compliance and treatment efficacy.
Segmentation Analysis
The market scope is segmented because of by Type, by Route of Administration, by Application, by Synthesis Technology, by Distribution Channel, by region.
Based on the Type of the market is segmented into Innovative Peptides, Generic Peptides.
Owing to current research and developments focusing on discovery of new drugs that are peptide-based and are expected to have efficacy, stability, and targeted actions, the new peptides market category leads in peptide therapeutics market. New or innovative peptides include newly patented medications intended to answer some unmet medical needs superiorly compared with existing treatments and these peptides could be engineered with higher bioavailability, longer half-life, better receptor specificity. For example, Semaglutide is a new GLP-1 receptor agonist primarily applied for the management of type 2 diabetes and obesity with an emphasis on better glycaemic control and weight loss.
Generic peptides are, on the other hand, off-patent versions of already approved peptide drugs. Since they are relatively less expensive compared to branded drugs, they provide cost-effective options for patients. These alternatives could help improve accessibility and affordability while maintaining therapeutic value comparable to the originator drugs. Buserelin represents a generic peptide for the treatment of prostate cancer and fertility drugs, which is also a GnRH analogue. Although the generic peptides increase the size of the market, these go through very rigid approval procedures under the regulatory authorities and face stiff competitions within the market. However, innovatory peptides remain the favourite since biotechnologies are still emerging, coupled by increasing demand for targeted peptide-based therapies.
By Route of Administration
Based on the Route of Administration of the market is segmented into Parenteral (Injectable), Oral, Others.
The parenteral route encompasses a vast market share of peptide therapeutics, largely because peptides have poor oral bioavailability and direct delivery into the bloodstream is deemed proper to ensure therapeutic activity. Parenteral peptides find delivery through subcutaneous, intravenous, or intramuscular injections, with this mechanism being the only way for these compounds to ensure fast absorption and stabilization. This is mainly used in cases of chronic diseases like diabetes, cancer, and metabolic disorders. For instance, Insulin, the peptide hormone for diabetic treatment, is mainly administered through subcutaneous injection to regulate blood sugar levels. Injectable GLP-1 receptor agonists like Semaglutide (Ozempic) also reflect the existence of this market.
However, advances in drug formulation have increasingly focused interest on oral peptides with the objective of enhancing patient convenience and compliance. Oral peptide drugs are hindered by enzymatic degradation and poor intestinal absorption, but new technologies such as lipid-based formulations and enzyme inhibitors are enhancing their viability. For example, Oral Semaglutide (Rybelsus) is the first FDA-approved oral GLP-1 receptor agonist for type 2 diabetes.
Others" would include alternative routes of administration, such as nasal, transdermal, and pulmonary, which are gaining acceptance for specific indications. For example, calcitonin nasal spray is an alternative to injectables for the treatment of osteoporosis.
By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. North America dominated the market in 2023 with a revenue share of over 45.63% due to the launch of effective products along with technologically advanced production facilities across the region. Moreover, the rising prevalence of diseases, such as cancer, cardiovascular disorders, respiratory diseases, infectious diseases, metabolic disorders, and others, is anticipated to propel market growth. For example, Cancer Atlas states that cancer is the leading cause of death in Canada, and the second leading cause of death after heart disease in the U.S. The disease accounts for about 1.9 million new cases in the region yearly. Cardiovascular diseases include stroke, heart disease, heart failure, and hypertension as the principal causes of death in the U.S.
The Asia Pacific region is likely to see tremendous growth in the near future due to various reasons, including unexploited opportunities, low raw material costs, increasing pool of outsourcing service providers, growth in the biotech sector, and more investment in R&D. The generic market is also expected to have tremendous CAGR on account of patent expiration of new drugs and decreasing raw material cost. All these aspects, therefore are forecasted to make the region abundant enough in opportunity growth.
List of Companies Profiled
- Eli Lilly and Company
- Pfizer Inc.
- Amgen Inc.
- Takeda Pharmaceutical Company Limited
- AstraZeneca
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Hoffmann-La Roche Ltd
- Novartis AG
- Novo Nordisk A/S
- GlaxoSmithKline plc.
- Ironwood Pharmaceuticals, Inc.
- Radius Health, Inc.
- Ipsen Pharma.
Report Coverage
The report will cover the qualitative and quantitative data on the Global Peptide Therapeutics Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.
Report Scope and Segmentations
Study Period | 2024-32 |
Base Year | 2023 |
Estimated Forecast Year | 2024-32 |
Growth Rate | CAGR of 5.63% % from 2024 to 2032 |
Segmentation | By Type, By Route of Administration, By Application, By Synthesis Technology, By Distribution Channel, By Region |
Unit | USD Million |
By Product Type | - Endoscopes
- Endoscopic Systems
- Consumables & Accessories
|
By Application | - Gastrointestinal (GI) Endoscopy
- Urology Endoscopy
- Pulmonology Endoscopy
- Other Applications
|
By End-User | - Hospitals
- Ambulatory Surgical Centres (ASCs)
- Other End-Users
|
By Region | - North America (U.S., Canada, Mexico)
- Europe (Germany, France, UK, Italy, Spain, Russia, Rest of Europe)
- Asia-Pacific (China, India, Japan, ASEAN, Rest of Asia-Pacific)
- Latin America (Brazil, Mexico, Rest of Latin America)
- MEA (Saudi Arabia, South Africa, UAE, Rest Of MEA)
|
Global Peptide Therapeutics Market Regional Analysis
North America accounted for the highest xx% market share in terms of revenue in the Peptide Therapeutics market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Peptide Therapeutics. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Peptide Therapeutics companies in economies such as Japan and China.
The objective of the report is to present comprehensive analysis of Global Peptide Therapeutics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.
Peptide Therapeutics Market Report is also available for below Regions and Country Please Ask for that
North America
Europe
- Switzerland
- Belgium
- Germany
- France
- U.K
- Italy
- Spain
- Sweden
- Netherland
- Turkey
- Rest of Europe
Asia-Pacific
- India
- Australia
- Philippines
- Singapore
- South Korea
- Japan
- China
- Malaysia
- Thailand
- Indonesia
- Rest Of APAC
Latin America
- Mexico
- Argentina
- Peru
- Colombia
- Brazil
- Rest of South America
Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- South Africa
- Rest Of MEA
Points Covered in the Report
- The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
- The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
- The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
- Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
- The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.
Key Questions
- How much the global Peptide Therapeutics Market valued?
- Which region has the largest share in 2024 for the global Peptide Therapeutics Market?
- What are the driving factors for the market?
- Which is the leading segment in the global market?
- What are the major players in the market?
Research Scope of Peptide Therapeutics Market
- Historic year: 2019- 2022
- Base year: 2023
- Forecast: 2024 to 2032
- Representation of Market revenue in USD Billion